Objective:

Deep brain stimulation of the subcallosal cingulate (SCC DBS) has been studied as a potential treatment for severe and refractory major depressive disorder since 2005. The authors used an open-label, long-term follow-up design to examine participants enrolled in a clinical trial of SCC DBS for treatment-resistant depression.

Methods:

Long-term outcome data were collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder; one patient in the major depression subgroup was later reclassified as having bipolar II disorder) receiving SCC DBS for 4–8 years.

Results:

Response and remission rates were maintained at ≥50% and ≥30%, respectively, through years 2–8 of the follow-up period. Three-quarters of all participants met the treatment-response criterion for more than half of their duration of participation in the study, with 21% of all patients demonstrating continuous response to treatment from the first year onward. Of 28 participants, 14 completed ≥8 years of follow-up, 11 completed ≥4 years, and three dropped out before 8 years. The procedure itself was generally safe and well tolerated, and there were no side effects of acute or chronic stimulation. The rate of medical or surgical complications was consistent with the rate observed in studies of DBS for other indications. There were no suicides.

Conclusions:

In >8 years of observation, most participants experienced a robust and sustained antidepressant response to SCC DBS.

中文翻译：

---

call门下扣带回的长期结果可治疗难治性抑郁症

客观的：

自2005年以来，已经研究了对brain部扣带回（SCC DBS）的深部脑刺激作为重症和难治性重度抑郁症的潜在治疗方法。作者使用了开放标签的长期随访设计，对参加临床研究的参与者进行了检查。 SCC DBS治疗难治性抑郁症的试验。

方法：

收集了28例接受SCC DBS治疗的患者（28例重度抑郁症患者和7例双相情感障碍II；长期抑郁亚组中的一名患者后来被归类为双相情感障碍II）的长期结果数据。

结果：

在随访期的2–8年中，缓解率和缓解率分别维持在≥50％和≥30％。所有参与者中有四分之三的患者在研究期间超过一半满足了治疗反应标准，所有患者中有21％从第一年开始就表现出对治疗的持续反应。在28名参与者中，有14名完成了≥8年的随访，11名完成了≥4年的随访，三名在8年之前退出。该过程本身通常是安全的且耐受性良好，并且没有急性或慢性刺激的副作用。内科或外科并发症的发生率与DBS在其他适应症研究中观察到的发生率一致。没有自杀。

结论：

在> 8年的观察中，大多数参与者对SCC DBS经历了强大而持续的抗抑郁反应。